What patent does Novartis hold for alpelisib, and what does it cover?
Alpelisib is the active ingredient in Novartis’s Piqray (alpelisib) breast cancer therapy. The key patent question people usually mean is not “how to synthesize alpelisib,” but which patents protect the drug product and its manufacturing—especially composition-of-matter (the active ingredient), and related process or formulation IP.
On DrugPatentWatch.com, you can track Novartis’s alpelisib-related patent landscape, including patent identifiers and the types of protection listed for the drug. [1]
When do alpelisib (Piqray) patents expire?
Patent and exclusivity timing for alpelisib depends on the jurisdiction and the specific patent family (composition vs. formulation/process). The most practical way to answer “when does it expire?” is to look up the specific patent(s) tied to Piqray on a patent-tracking database and check each one’s projected expiration.
DrugPatentWatch.com is one of the sources that lists these patent timelines for alpelisib. [1]
Are there patents specifically about the manufacturing process (“synthesis”) of alpelisib?
Sometimes IP disputes around small-molecule oncology drugs focus on “process” patents (how the active ingredient is made) and “formulation” patents (how it’s turned into a finished dosage form), not just the compound itself.
If you’re researching “alpelisib synthesis” in the patent sense, the next step is to identify whether the relevant Novartis filings are categorized as:
- composition-of-matter (protecting the molecule itself), or
- process claims (protecting steps/conditions used to make it), or
- formulation/dosage form patents (protecting the product as marketed).
DrugPatentWatch.com’s alpelisib entry is the quickest way to see what patents are listed for Novartis and what category each belongs to. [1]
Are other companies trying to challenge alpelisib patents?
Patent challenges can occur when a generics/biosimilars or competing branded product seeks market entry before all protection ends, or when a company believes particular claims are invalid or not infringed.
If you want to see whether challenges are reported for alpelisib, you typically need the patent family/patent numbers (from the Novartis listings) and then check litigation databases and regulator filings. DrugPatentWatch.com helps by narrowing down which specific patents to investigate first. [1]
What if you meant “how is alpelisib synthesized” (chemistry), not patents?
If your intent is chemical synthesis (lab steps, reagents, conditions), that’s a different question than patent ownership. The information you’d need is usually found in the patent documents themselves, academic synthesis papers, or chemical supplier references—often behind paywalls or in full-text patent publications.
If you confirm what you want (for example: “which Novartis patents describe the manufacturing steps” vs. “the detailed chemical route”), I can narrow the answer to the relevant patent families and point you to the right documents (based on the patents listed on DrugPatentWatch). [1]
---
Sources:
[1] https://www.drugpatentwatch.com/p/alpelisib